A detailed history of First Trust Advisors LP transactions in Sarepta Therapeutics, Inc. stock. As of the latest transaction made, First Trust Advisors LP holds 464,916 shares of SRPT stock, worth $54.1 Million. This represents 0.06% of its overall portfolio holdings.

Number of Shares
464,916
Previous 101,916 356.18%
Holding current value
$54.1 Million
Previous $16.1 Million 260.63%
% of portfolio
0.06%
Previous 0.02%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$124.33 - $156.75 $45.1 Million - $56.9 Million
363,000 Added 356.18%
464,916 $58.1 Million
Q2 2024

Aug 13, 2024

BUY
$113.33 - $163.85 $11.6 Million - $16.7 Million
101,916 New
101,916 $16.1 Million
Q4 2023

Feb 13, 2024

BUY
$67.31 - $124.76 $92,618 - $171,669
1,376 Added 0.32%
432,350 $41.7 Million
Q3 2023

Nov 13, 2023

SELL
$102.5 - $123.59 $17.8 Million - $21.4 Million
-173,362 Reduced 28.69%
430,974 $52.2 Million
Q2 2023

Aug 14, 2023

SELL
$106.4 - $157.19 $9.07 Million - $13.4 Million
-85,276 Reduced 12.37%
604,336 $69.2 Million
Q1 2023

May 15, 2023

SELL
$117.53 - $155.99 $2.15 Million - $2.86 Million
-18,334 Reduced 2.59%
689,612 $95 Million
Q4 2022

Feb 09, 2023

SELL
$100.86 - $132.13 $21.1 Million - $27.7 Million
-209,296 Reduced 22.82%
707,946 $91.7 Million
Q3 2022

Nov 14, 2022

BUY
$75.71 - $119.24 $17.2 Million - $27.1 Million
226,947 Added 32.88%
917,242 $101 Million
Q2 2022

Aug 12, 2022

SELL
$62.69 - $88.44 $10.6 Million - $15 Million
-169,453 Reduced 19.71%
690,295 $51.7 Million
Q1 2022

May 13, 2022

SELL
$63.15 - $90.42 $2.48 Million - $3.55 Million
-39,308 Reduced 4.37%
859,748 $67.2 Million
Q4 2021

Feb 08, 2022

SELL
$77.28 - $99.42 $2.33 Million - $3 Million
-30,152 Reduced 3.24%
899,056 $81 Million
Q3 2021

Nov 15, 2021

BUY
$65.97 - $92.48 $3.75 Million - $5.26 Million
56,916 Added 6.52%
929,208 $85.9 Million
Q2 2021

Oct 12, 2021

SELL
$69.38 - $86.75 $378,814 - $473,655
-5,460 Reduced 0.62%
872,292 $67.8 Million
Q2 2021

Aug 16, 2021

SELL
$69.38 - $86.75 $563,296 - $704,323
-8,119 Reduced 0.92%
877,752 $68.2 Million
Q1 2021

May 14, 2021

BUY
$72.25 - $168.95 $25.2 Million - $59 Million
349,454 Added 65.15%
885,871 $66 Million
Q4 2020

Feb 02, 2021

SELL
$125.56 - $178.74 $6.37 Million - $9.07 Million
-50,749 Reduced 8.64%
536,417 $91.5 Million
Q3 2020

Nov 05, 2020

SELL
$127.12 - $172.34 $10.4 Million - $14.1 Million
-81,870 Reduced 12.24%
587,166 $82.5 Million
Q2 2020

Jul 22, 2020

BUY
$93.0 - $171.7 $12.9 Million - $23.8 Million
138,658 Added 26.14%
669,036 $107 Million
Q1 2020

May 06, 2020

SELL
$82.38 - $131.64 $5.65 Million - $9.03 Million
-68,590 Reduced 11.45%
530,378 $51.9 Million
Q4 2019

Feb 03, 2020

SELL
$76.53 - $135.58 $5.38 Million - $9.54 Million
-70,352 Reduced 10.51%
598,968 $77.3 Million
Q3 2019

Nov 04, 2019

SELL
$72.81 - $156.91 $14.9 Million - $32.1 Million
-204,541 Reduced 23.41%
669,320 $50.4 Million
Q2 2019

Jul 30, 2019

BUY
$112.21 - $151.95 $87 Million - $118 Million
775,458 Added 788.04%
873,861 $133 Million
Q1 2019

May 09, 2019

SELL
$106.67 - $151.68 $29.6 Million - $42 Million
-277,202 Reduced 73.8%
98,403 $11.7 Million
Q4 2018

Feb 07, 2019

BUY
$97.32 - $148.76 $13.5 Million - $20.6 Million
138,218 Added 58.22%
375,605 $41 Million
Q3 2018

Oct 25, 2018

BUY
$115.31 - $161.51 $20 Million - $28.1 Million
173,782 Added 273.22%
237,387 $38.3 Million
Q2 2018

Aug 02, 2018

BUY
$71.74 - $153.69 $837,062 - $1.79 Million
11,668 Added 22.47%
63,605 $8.41 Million
Q1 2018

Apr 23, 2018

BUY
$54.02 - $82.27 $489,799 - $745,942
9,067 Added 21.15%
51,937 $3.85 Million
Q4 2017

Feb 08, 2018

SELL
$47.64 - $56.75 $704,976 - $839,786
-14,798 Reduced 25.66%
42,870 $2.39 Million
Q3 2017

Oct 24, 2017

BUY
$35.73 - $47.15 $2.06 Million - $2.72 Million
57,668
57,668 $2.62 Million

Others Institutions Holding SRPT

About Sarepta Therapeutics, Inc.


  • Ticker SRPT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 87,567,904
  • Market Cap $10.2B
  • Description
  • Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...
More about SRPT
Track This Portfolio

Track First Trust Advisors LP Portfolio

Follow First Trust Advisors LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of First Trust Advisors LP, based on Form 13F filings with the SEC.

News

Stay updated on First Trust Advisors LP with notifications on news.